In early March, Hospira announced the recall of lot 42-120-JT of the magnesium sulfate in 5% dextrose injection, because the barcode on the bag may actually be the machine readable barcode for 1000 mL bags of heparin sodium two units per milliliter. According to the FDA, the company voluntarily issued the recall. [click to continue…]
A mid-January directive to state survey agencies provides new details about Medicare’s expectations for pharmacy activities and compounding practices at critical access hospitals. [click to continue…]
Teva pharmaceuticals announced in early March that – due to incompatibility between an ingredient in their Treanda (bendamustine) injection and components of some closed system transfer devices, adapters, and syringes – some may experience failure of equipment and/or contamination of the drug. [click to continue…]
A bipartisan group of legislators in the House of Representatives reintroduced a bill to allow Medicare to cover state authorized pharmacist services. The bill, known as the Pharmacy in Medically Underserved Areas Enhancement Act, makes the same changes to the Social Security Act proposed by HR 4190, first introduced last year. The text of the new bill, known as HR 592, is publicly available online. [click to continue…]
At the end of January, the FDA announced approval for Bexsero, a Novartis vaccine designed to protect against invasive meningococcal disease caused by the serogroup B bacteria, Neisseria meningitidis. [click to continue…]
Colorectal cancer is the fourth most common cancer in America, and the second leading cause of death from cancer. It affects people across all racial and ethnic groups, but is most commonly found in people over age 50.
If all patients over age 50 were screened on a regular basis, 60% of deaths from colorectal cancer could be prevented. Use this month to raise awareness about colorectal cancer screenings and prevention in your community. [click to continue…]